Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a selective β1‑adrenergic receptor blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for improving outcomes in patients with chronic heart failure, primarily in adult populations.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory conformity and reliable logistics for global distribution.

Nebivolol is a β1‑selective blocker used in cardiovascular therapy.

Hypertension: lowers systolic and diastolic blood pressure by reducing cardiac output and peripheral vascular resistance. Heart failure: improves left‑ventricular ejection fraction and reduces mortality in chronic heart failure patients. Cardiovascular risk management in hypertensive patients: contributes to overall risk reduction by providing vasodilatory nitric‑oxide effects.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general weakness. - Bradycardia: slower than normal heart rate. - Nausea or mild gastrointestinal upset. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to syncope. - Bronchospasm in patients with asthma or COPD. - Acute heart failure decompensation. - Allergic reactions such as rash, pruritus, or angioedema. - Elevated liver enzymes indicating hepatic involvement.

Before initiating Nebivolol, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Use caution in asthma/COPD: β‑blockade may exacerbate bronchospasm. Adjust dose in renal/hepatic impairment: reduced clearance may require lower dosing. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: risk of excessive bradycardia and hypotension. - Calcium‑channel blockers verapamil or diltiazem: can increase plasma levels of nebivolol. - Anti‑arrhythmic agents such as amiodarone: may potentiate cardiac conduction effects. - Clonidine withdrawal: sudden stop of clonidine while on nebivolol can cause severe hypertension. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise nebivolol concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Diuretics: may increase risk of electrolyte disturbances and hypotension. - NSAIDs: can blunt antihypertensive response. - Antidiabetic drugs: nebivolol may mask hypoglycaemic symptoms. - Certain antidepressants (e.g., sertraline): monitor for bradycardia.